The substantial reduction in risk of kidney disease seen in a trial of canagliflozin in patients with type 2 diabetes is likely to be a class effect of the SGLT2 inhibitors, Australian study investigators say. A randomised controlled trial involving more than 4400 patients with type 2 diabetes and albuminuric chronic kidney disease found that ...
SGLT2 inhibitor renal protection “a class effect”
By Michael Woodhead
18 Apr 2019